Novo Nordisk (NYSE:NVO) continues to attract attention as investors weigh its role in obesity and diabetes care against recent share price moves. The stock closed at $46.48, with mixed returns over the past year.

See our latest analysis for Novo Nordisk.

The recent 1-day share price return of 1.68% follows a weaker 30-day share price return of 6.31% and a 1-year total shareholder return that declined 11.49%. Short-term momentum is trying to recover, while longer-term performance still reflects caution.

If Novo Nordisk has you thinking about where the next opportunity in healthcare might come from, it can be useful to scan for other focused plays in the space using 42 healthcare AI stocks

Bulls view Novo Nordisk as a focused obesity and diabetes leader trading below some estimates of intrinsic value. Bears point to the weak multi-year returns. Which side does the current valuation actually support next?

Most Popular Narrative: 54.9% Undervalued

The most followed narrative values Novo Nordisk at $102.97 per share compared with the recent close at $46.48. That wide gap hinges on a few specific growth triggers.

Recent success in a phase IIIa trial showed once-daily doses of oral semaglutide demonstrated a statistically significant and superior reduction in HbA1c by 0.83% versus placebo at 26 weeks for adolescents with Type II diabetes. Based on the study data, NVO intends to seek regulatory approval for oral semaglutide in adolescents aged 10 to 17 with T2D for both Rybelsus and oral Ozempic in the U.S. and the EU in the second half of the year. Due to a lack of effective treatment options for adolescents with T2D, NVO will benefit greatly from having the only approved treatment for the 20.9 million adolescents with T2D. As the only player in this market NVO would see increased revenue growth and margin expansion, restoring much of the growth narrative that has softened in recent years.

Read the complete narrative.

According to MCOInvestors, this fair value rests on a very specific playbook. It leans on moderated revenue growth, higher margins, and a future earnings multiple that implies renewed confidence in Novo Nordisk.

Result: Fair Value of $102.97 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Novo Nordisk still faces real risks if oral semaglutide approvals are delayed or if GLP-1 market growth projections and compounding rule changes do not occur as expected.

Find out about the key risks to this Novo Nordisk narrative.

Next Steps

With Novo Nordisk pulling in both cautious and optimistic views, it makes sense to move quickly and test the narrative against the underlying data yourself. A good place to start is by weighing the balance of risks and rewards in the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Novo Nordisk?

If Novo Nordisk has sharpened your interest in quality opportunities, do not stop here. Use targeted stock ideas to keep your portfolio thinking two steps ahead.

• Spot potential value plays early and scan through 52 high quality undervalued stocks that combine solid fundamentals with attractive pricing.
• Strengthen the defensive side of your portfolio by reviewing 78 resilient stocks with low risk scores that aim to keep volatility in check.
• Seek out future leaders before the crowd notices and comb through a screener containing 20 high quality undiscovered gems that might otherwise stay off your radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.